From EULAR 2024 - Gerd Burmester, MD: Long-Term Data Supports Upadacitinib's Safety in Rheumatic Disease Treatment
In an interview with HCPLive, Gerd Burmester, MD, professor of medicine in the Department of Rheumatology and Clinical Immunology at the Charité University Hospital, Free University of Berlin, and Humboldt University of Berlin, Germany, discusses the results of a study analyzing the long-term safety of upadacitinib treatment among patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA).
A team of investigators led by Burmester used data from the SELECT clinical program, including 11 phase 3 upadacitinib trials. A total of 4998 patients (RA, n = 3209; PsA, n = 907; AS, n = 596; nr-axSpA, n = 286) received ≥ 1 dose of upadacitinib 15 mg, totaling 15,895.8 patient-years of exposure. The majority of exposure was derived from RA studies.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
